A Phase III, Randomized, Open-Label Multicenter, International Study Comparing The Combination Of SU5416 [semaxinib]/Irinotecan/5-Fluorouracil/Leucovorin [folinic acid] Versus Irinotecan/Fluorouracil/Leucovorin Alone As First-Line Therapy Of Patient With Previously Untreated Metastatic Colorectal Cancer

Trial Profile

A Phase III, Randomized, Open-Label Multicenter, International Study Comparing The Combination Of SU5416 [semaxinib]/Irinotecan/5-Fluorouracil/Leucovorin [folinic acid] Versus Irinotecan/Fluorouracil/Leucovorin Alone As First-Line Therapy Of Patient With Previously Untreated Metastatic Colorectal Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2005

At a glance

  • Drugs Semaxanib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top